SAN DIEGO, June 24, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first public cannabis company in the United States to establish the world’s first-ever cannabis-derived nutraceuticals Products, Brands and Supply Chains, announced today that its subsidiary HempMeds® welcomes five-time Brazilian wrestling champion and professional UFC fighter Raoni Barcelos as the company’s new spokesperson.
Born in Rio De Janeiro, Barcelos is a former amateur wrestler and grappler and currently a professional mixed martial artist (MMA). Barcelos has been an active bantamweight fighter for nine years.
“We are excited to begin this new project and to work with professional athletes around the world who can potentially improve their wellbeing by taking our products,” said Raul Elizalde, CEO of HempMeds®. “We believe his testimony will help the public understand its potential benefits.”
In addition to his titles in Brazil, Barcelos is also a two-time South American wrestling champion and was featured twice with the UFC at the “Fight of the Night”. Barcelos is also a three-time featherweight champion of the Resurrection Fighting Alliance. In his MMA career, he has won 16 fights with 8 knockouts.
“I used HempMeds CBD products to aid recovery after long days of training and strenuous battle plans,” said Barcelos. “I hope to share my knowledge with athletes around the world who might benefit from using CBD but are afraid to use the products or don’t know how to use them.”
Fans can fight Barcelos against Timur Valieve during UFC Fight Night: Gane vs. Volkov on Saturday June 26, 2021.
To learn more about HempMeds®, please visit the company online at www.hempmedspx.com.
About Medical Marihuana, Inc.
We are a firsts® company. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct businesses in the non-psychoactive cannabinoids space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest quality legal non-psychoactive cannabis products made from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners such as AXIM® Biotechnologies, Inc. and Neuropathix. Medical Marijuana, Inc. has been recognized as a premier CBD producer by CNBC. Medical Marijuana, Inc. was also the first to obtain historic import permits for CBD products from the governments of Brazil, Mexico, Argentina and Paraguay and is a leader in developing international markets. The company’s flagship product, Real Scientific Hemp Oil, has been used in several successful clinical trials across Mexico and Brazil to understand its safety and effectiveness.
Medical Marijuana, Inc. is headquartered in San Diego, California. Additional information is available at OTCMarkets.com or www.medicalmarijuanainc.com. Click here to watch Medical Marijuana, Inc. corporate video.
Shareholders and consumers are also encouraged to purchase CBD oil and other products from the Medical Marijuana, Inc. store.
FORWARD LIABILITY DISCLAIMER
This press release may contain certain forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the safe harbor established by those sections. This material contains statements about expected future events and / or financial results that are forward-looking and involve risks and uncertainties. Such forward-looking statements, by definition, involve risks, uncertainties and other factors that could cause the actual results, performance or accomplishments of Medical Marijuana, Inc. to differ materially from the statements made herein.
FOOD AND DRUG ADMINISTRATION DISCLOSURE (FDA)
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Medical Marijuana, Inc. does not sell or distribute products that violate United States Controlled Substances Act.
Contact person for public relations:
Investor Relations Contact:
Pp. (858) 283-4016